## **Genetics in Clinical Cancer Care: Controversies, Insights & Scalable Solutions**

April 22-24, 2022

## Friday April 22<sup>nd</sup>,2022

| 7:00am-7:30am   | Continental Breakfast and Registration  |  |
|---|---|--|
| 7:30am-8:30am   | Pre-Conference Genetics 101 Basic Concepts  |  |
| 7:30am  | Primer on Genetic Counseling  | Feighanne Hathaway, MS, LCGC   |
| 7:50am  | Primer on Genomics  | Michael Drazer, MD, PhD  |
| 8:10am  | Primer on Al  | Frederick Howard, MD   |
| 8:30am  | Welcome Address   | Olufunmilayo Olopade, MBBS,  |
|   |   | FASCO  |
|   | Advanced concepts in germline genomic   | Moderator:   |
|   | testing: Refining Hereditary Risk   | Allison DePersia, MD   |
|   |   | Iris Romero, MD  |
| 8:35am  | Making sense of panel testing for inherited   | Jane Churpek, MD   |
|   | hematologic malignancies  |  |
| 8:55am  | Polygenic risk score: Should clinicians use it?   | Montserrat Garcia-Closas, MD,  |
|   |   | DrPH   |
| 9:15am  | Keynote Address I:  | Laura Esserman, MD, MBA  |
|   | State of the Art in Breast Cancer Prevention:   |  |
|   | Defining healthy women at high risk in the  |  |
|   | Wisdom Study  |  |
| 9:45am  | Q & A with Speakers   |  |
|   |   |  |
| 10:00am   | Break   |  |
|   |   | Moderators:  |
|   | Break   | Nan Chen, MD   |
| 10:00am   | Break  Dawn of a New Era for BRCA Mutation Carriers   | Nan Chen, MD<br>Iris Romero, MD  |
| 10:00am<br>10:30am  | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer   | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD   |
| 10:00am   | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring   | Nan Chen, MD<br>Iris Romero, MD  |
| 10:00am<br>10:30am  | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in  | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD   |
| 10:00am<br>10:30am<br>10:50am                                 | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer  Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women   | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD<br>Rita Nanda, MD   |
| 10:00am<br>10:30am  | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II:   | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD   |
| 10:00am<br>10:30am<br>10:50am                                 | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies  | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD<br>Rita Nanda, MD   |
| 10:00am<br>10:30am<br>10:50am                                 | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease   | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD   |
| 10:00am<br>10:30am<br>10:50am                                 | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of  | Nan Chen, MD<br>Iris Romero, MD<br>Kunle Odunsi, MD, PhD<br>Rita Nanda, MD   |
| 10:00am  10:30am  10:50am  11:10am                            | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers   | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD  Kathryn Mills, MD                                      |
| 10:00am<br>10:30am<br>10:50am                                 | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease  Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers Outliving Risk: An age-related assessment of   | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD   |
| 10:00am  10:30am  10:50am  11:10am  11:40am  12:00pm          | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers Outliving Risk: An age-related assessment of cancer risk and its impact on management                     | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD  Kathryn Mills, MD                                      |
| 10:00am  10:30am  10:50am  11:10am  11:40am  12:00pm  12:20pm | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers Outliving Risk: An age-related assessment of cancer risk and its impact on management Q & A with Speakers | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD  Kathryn Mills, MD  Shari Snow, MD                      |
| 10:00am  10:30am  10:50am  11:10am  11:40am  12:00pm          | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers Outliving Risk: An age-related assessment of cancer risk and its impact on management                     | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD  Kathryn Mills, MD  Shari Snow, MD  Discussion leaders: |
| 10:00am  10:30am  10:50am  11:10am  11:40am  12:00pm  12:20pm | Break  Dawn of a New Era for BRCA Mutation Carriers  Advances in Immunotherapy for Ovarian Cancer Heterogeneity of Breast Cancer; tailoring treatments to reduce long term toxicities in young women  Keynote Address II: State of the Art for BRCA Directed Therapies early stage through metastatic disease Lessons Learned in the Primary Prevention of Ovarian Cancer in BRCA Mutation Carriers Outliving Risk: An age-related assessment of cancer risk and its impact on management Q & A with Speakers | Nan Chen, MD Iris Romero, MD Kunle Odunsi, MD, PhD Rita Nanda, MD  Mark Robson, MD  Kathryn Mills, MD  Shari Snow, MD                      |

|        |   | Catherine Marcum, DNP, APN   |
|--------|---|------------------------------|
|        |   | Susan Shehayeb, MS, CGC      |
| 1:30pm | Lunch: Non -CME Activities                    | Gold Room                    |
|        | Cancer IQ Ancillary Event                     |                              |
| 2:30pm | Keynote III:                                  | Steve Narod, MD              |
|        | Distinguished Lecturer:                       |                              |
|        | Treatment of BRCA1-positive breast cancer: an |                              |
|        | observational study                           |                              |
| 3:00pm | Q & A with Dr. Narod (No Audience Response    | Olufunmilayo Olopade, MBBS,  |
|        | System)                                       | FASCO                        |
|        | BRCA & Men's Health                           | Moderators:                  |
|        |   | Russell Szmulewitz, MD       |
|        |   | Shari Snow, MD               |
| 3:15pm | Uptake of Genetic Testing in Prostate Cancer  | Elias Obeid, MD              |
|        | Families                                      |                              |
| 3:35pm | Genetic Evaluation of Prostate Cancer:        | Veda Giri, MD                |
|        | Considerations for Practice                   |                              |
| 3:55pm | Genetics of Breast Cancer in Men              | Susan Neuhausen, PhD         |
| 4:15pm | BRCA2-associated male breast cancer: should   | Nora Jaskowiak, MD           |
|        | there be a different surgical approach?       |                              |
| 4:35pm | Q & A with Speakers                           |                              |
| 4:45pm | Break   |                              |
| 5:00pm | Case Presentations                            | Discussion leaders:          |
|        |   | Rachelle Manookian, MS, CGC  |
|        |   | Christine Drogan, MS, CGC    |
|        |   | Feighanne Hathaway, MS, LCGC |
|        |   | Catherine Marcum, DNP, APN   |
| 6:00pm | Poster Reception sponsored by Natera -        |                              |
|        | International Ballroom Foyer                  |                              |

## Saturday April 23<sup>rd</sup>, 2022

| 7:30am | Continental Breakfast                          |                              |
|--------|--|------------------------------|
| 8:00am | Announcements                                  | Sonia S. Kupfer, MD, AGAF    |
|        | CGA-IGC Collaborative Session on Inherited GI  | Moderators:                  |
|        | Cancers  | Sonia Kupfer, MD             |
|        |  | Christine Drogan, MS, LCGC   |
| 8:05am | Keynote Address IV:                            | Stephen Gruber, MD, PhD, MPH |
|        | Colorectal Cancer Genetics: High Risk,         |                              |
|        | Moderate Risk, and Polygenic Risk Scores       |                              |
| 8:30am | Mainstreaming genetic counseling for inherited | Heather Hampel, MS, CGC      |
|        | Colorectal Cancer                              |                              |
| 8:50am | Keynote Address V:                             | Bryson Katona, MD, PhD       |
|        | Pancreatic Cancer Surveillance –Does it work?  |                              |
| 9:15am | Targeted therapies for GI Cancers              | Michael Hall MD, MS          |

| 9:35am           | Managing Families with inherited Endocrine  | Xavier Keutgen, MD  |
|------------------|---|---|
|                  | Cancer Syndrome —Paraganglioma, VHL   | ,   |
| 10:00am          | Q & A with Speakers   |   |
| 10:15am          | Break   |   |
|                  | Integrating Pharmacogenomics to Cancer Care to Optimize Clinical Outcomes                             | Moderators:<br>Loren Saulsberry, PhD<br>Tien Truong, PharmD, PhD  |
| 10:45am          | Uncovering ancestry vs. race, how studies in Europe can miss important alleles in others              | Minoli Perera, PhD  |
| 11:05am          | <b>Keynote VI:</b> New developments in genotype-guided dosing of 5-Fluorouracil                       | Steven Offer, PhD   |
| 11:30am          | Germline Pharmacogenomic testing in Cancer therapeutics: Considerations for clinical practice in 2022 | Peter O'Donnell, MD   |
| 11:45am          | Q & A with Speakers   |   |
| 12:00pm          | Case Presentations  | Moderators: Lauren Gima, MS, CGC Rachelle Manookian, MS CGC Madeline Pies MS, LCGC Elise Sobotka, MS, CGC, MPH                          |
| 1:00pm           | Lunch-Non CME Activities  |   |
|                  | Global Perspectives   | Moderators: Rodrigo Guindalini, MD, PhD Catherine Marcum, DNP, APN  |
| 2:00pm           | Keynote Address VII:<br>Inequities in Gene-based Care   | Tuya Pal, MD  |
| 2:25pm           | Uptake of Bilateral Salpingo-Oophorectomy in Women with a BRCA1 or BRCA2 mutation: Can We Do Better?  | Kelly Metcalfe, RN, PhD   |
| 2:45pm           | <b>Keynote Address VII:</b> Population Risk stratification for Breast Cancer                          | Gareth Evans, MD, FRCP  |
| 3:10pm           | Population Genetics of Inherited Cancers in Israel  | Gad Rennert, MD, PhD  |
|                  |   |   |
| 3:30pm           | Addressing the burden of Inherited Cancers in India   | Raja Pramanik MD, DM  |
| 3:30pm<br>3:50pm | Addressing the burden of Inherited Cancers in   | Raja Pramanik MD, DM  |
|                  | Addressing the burden of Inherited Cancers in India   | Raja Pramanik MD, DM  |
| 3:50pm           | Addressing the burden of Inherited Cancers in India  Q & A with Speakers                              | Raja Pramanik MD, DM  Moderators: Kathleen Blazer, EdD, CGC, MS Susan Shehayeb, MS, CGC Lauren Gima, MS, CGC Elise Sobotka MS, CGC, MPH |

## Sunday April 24<sup>th</sup>, 2022

| 8:00am  | Continental Breakfast                               |                             |
|---------|---|-----------------------------|
| 8:25am  | Announcements                                       | Sonia Kupfer, MD            |
|         | Population Health Management & the Al               | Moderators:                 |
|         | Revolution  | Pamela Ganschow, MD         |
|         |   | Lydia Usha, MD              |
| 8:30am  | Keynote address IX:                                 | Stacy Gray, MD, AM          |
|         | Leveraging informatics tools to assess and          |                             |
|         | improve cancer genetics care                        |                             |
| 8:55am  | Advances in Digital Pathology and AI to             | Fred Howard, MD             |
|         | democratize access to care                          | Trea riowara, wib           |
| 9:15 am | New models of Image Based Biomarkers for            | Gregory Karczmar, PhD       |
|         | Breast and Prostate Cancer Screening                |                             |
| 9:35am  | Liquid Biopsies as a surveillance tool: Identifying | Olufunmilayo Olopade, MBBS, |
|         | cancers and carriers early – Are we there yet?      | FASCO                       |
| 9:55am  | Q & A with Speakers                                 |                             |
| 10:00am | Multidisciplinary Patient Advocacy Panel            | Moderators:                 |
|         | Discussion  | Karen Hurley, PhD           |
|         |   | Patients:                   |
|         |   | Michelle Weaver Knowles     |
|         |   | Karl Surkan,PhD             |
|         |   | Alicia Cook                 |
| 11:00am | Next Generation Research: Questions for the         | Olufunmilayo Olopade, MBBS, |
|         | Network   | FASCO                       |
|         |   | Sonia Kupfer, MD            |
| 11:45am | Adjourn   |                             |